Clover Biopharmaceuticals, Ltd.

Equities

2197

KYG2280A1076

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 EDT			5-day change	1st Jan Change
0.395 ^HKD	-.--%		-7.06%	-36.29%

04-12	Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding	CI
04-08	Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial	MT

Clover Biopharmaceuticals, Ltd. Appoints Nicholas Jackson as President of Global Research and Development

February 01, 2022 at 09:00 am

Clover Biopharmaceuticals, Ltd. announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development. Dr. Jackson will work closely with the company's CEO, Joshua Liang, to accelerate the development of Clover's existing pipeline candidates and nominate new product candidates.

Latest news about Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding	04-11	CI
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial	04-08	MT
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort	04-08	CI
Clover Biopharmaceuticals, Ltd. announced that it expects to receive $0.320713 million in funding	04-01	CI
Clover Biopharmaceuticals Trims Losses in 2023	03-27	MT
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	01-12	MT
Clover Biopharmaceuticals Publishes Positive Results from SCB-219M Clinical Trial	12-29	MT
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia	12-28	CI
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%	12-12	MT
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate	12-12	CI
Clover Biopharmaceuticals Completes Submission of Application for Seasonal Flu Vaccine in Brazil	11-06	MT
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil	11-06	CI
Clover Biopharmaceuticals Rolls Out Quadrivalent Seasonal Influenza Vaccine in Mainland China	23-09-11	MT
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	23-09-11	CI
Clover Biopharmaceuticals Swings to Profit in H1	23-08-22	MT
Clover Biopharmaceuticals CEO Boosts Shareholding	23-08-22	MT
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Slowdown in China's Industry, Retail Keep Hong Kong Stocks in Slump; Clover Biopharmaceuticals Drops 7%	23-08-15	MT
Clover Biopharmaceuticals Expects Swing to Profit in H1	23-08-13	MT
Clover Biopharmaceuticals, Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Six Months Ended June 30, 2023	23-08-13	CI
Clover Biopharmaceuticals' First-Half Expenses Fall 50%; Shares Jump 7%	23-07-10	MT
Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development	23-07-10	CI
Clover Biopharmaceuticals to Expand Distribution, Sales of Flu Shot with Keyuan Xinhai Deal	23-05-24	MT
Clover Biopharmaceuticals, Ltd. Establishes Commercial Partnership with Keyuan Xinhai Medical Products Trading Co. Ltd	23-05-23	CI

Chart Clover Biopharmaceuticals, Ltd.

Duration

Period

More charts

Company Profile

Clover Biopharmaceuticals Ltd is a China-based company mainly engaged in pharmaceutical business. The Company's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The Company's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CLOVER BIOPHARMACEUTICALS, LTD.	-36.29%	65.54M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs